CVRX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: February 25, 2026
Report Source: 2025 Annual Report
CVRx Inc. Stock Analysis CVRX
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 223 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
Read More CVRx Inc (CVRX) Chart
Key Statistics of CVRx Inc (CVRX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$5.70Volume
1.07MP/E Ratio (TTM)
-52 Week Range
Market Cap
198.23MAvg. Volume
369.71KDividend Yield
-Financial Metrics & Statements of CVRx Inc (CVRX)
FAQ's for CVRx Inc (CVRX)
- According to Musaffa’s Shariah screening methodology, CVRx Inc (CVRX) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.